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Abstract
Chronic pain is a complex trait that is moderately heritable and genetically, as well as phenotypically, correlated with
major depressive disorder (MDD). Use of the conditional false discovery rate (cFDR) approach, which leverages
pleiotropy identiﬁed from existing GWAS outputs, has been successful in discovering novel associated variants in
related phenotypes. Here, genome-wide association study outputs for both von Korff chronic pain grade and for MDD
were used to identify variants meeting a cFDR threshold for each outcome phenotype separately, as well as a
conjunctional cFDR (ccFDR) threshold for both phenotypes together. Using a moderately conservative threshold, we
identiﬁed a total of 11 novel single nucleotide polymorphisms (SNPs), six of which were associated with chronic pain
grade and nine of which were associated with MDD. Four SNPs on chromosome 14 were associated with both chronic
pain grade and MDD. SNPs associated only with chronic pain grade were located within SLC16A7 on chromosome 12.
SNPs associated only with MDD were located either in a gene-dense region on chromosome 1 harbouring LINC01360,
LRRIQ3, FPGT and FPGT-TNNI3K, or within/close to LRFN5 on chromosome 14. The SNPs associated with both outcomes
were also located within LRFN5. Several of the SNPs on chromosomes 1 and 14 were identiﬁed as being associated
with expression levels of nearby genes in the brain and central nervous system. Overall, using the cFDR approach, we
identiﬁed several novel genetic loci associated with chronic pain and we describe likely pleiotropic effects of a recently
identiﬁed MDD locus on chronic pain.
Introduction
Chronic pain is deﬁned as pain lasting longer than
12 weeks. It affects around 30% of the global adult
population1, imposes signiﬁcant socioeconomic burden,
and contributes to excess mortality2,3. Chronic pain is
often associated with both speciﬁc and non-speciﬁc
medical conditions (such as cancers and HIV/AIDS,
ﬁbromyalgia and musculoskeletal conditions), and with a
range of injuries4,5. It is also commonly co-morbid with
mood disorders, such as major depressive disorder
(MDD)6–8. MDD is a common and serious mood disorder
involving psychological symptoms such as persistent low
mood and anhedonia, and physical symptoms such as
changes in appetite and sleep disturbance (American
Psychiatric Association 2013). In common with chronic
pain, MDD also imposes a signiﬁcant socioeconomic
burden worldwide and is now the leading cause of dis-
ability globally2. The causal direction of factors underlying
the association between chronic pain and mood disorders
is unclear.
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Genetics of chronic pain and related disorders
The genetics of pain have hitherto mostly been inves-
tigated using candidate gene and animal-model approa-
ches9,10. Several aspects of chronic pain, such as chronic
pain grade (a graded classiﬁcation of chronic pain asses-
sed using a questionnaire ﬁrst constructed by von Korff
and colleagues11 and further validated by Smith et al.12),
pain at speciﬁc sites (e.g. back pain), and speciﬁc chronic-
pain-related conditions such as migraine and tempor-
omandibular joint (TMJ) disorder, have been shown to be
complex traits with moderate heritability and associated
genetic variants have been discovered3,7,9,10,13–15. In order
to be suitably well-powered genome-wide association
studies of complex traits (such as chronic pain) must be of
sufﬁcient sample size (>~2000 individuals), amongst other
restrictions (see Hong et al.16). However, in part due to
the heterogeneity of pain assessment and pain experi-
ence17, there are very few large-scale genetic studies of
chronic pain as a phenotype in its own right irrespective
of site, inciting injury or condition9,10,14,18 and no
genome-wide signiﬁcant genetic variants have yet been
identiﬁed for chronic pain grade speciﬁcally.
Chronic pain and chronic pain disorders are often
comorbid with psychiatric and neurodevelopmental dis-
orders, including MDD19. MDD has also been shown to
be genetically correlated with chronic pain grade speciﬁ-
cally (rg= 0.53
7), and shared genetic factors have been
reported between some speciﬁc chronic pain conditions
and MDD20–22. Chronic pain and depression can also be
grouped together into ‘Chronic Pain Syndromes’, a
poorly-deﬁned range of syndromes involving chronic pain
and exhibiting genetic overlap23.
The immune and nervous systems play a central role in
chronic pain development and maintenance24,25. Simi-
larly, obesity and chronic pain are often comorbid, with
extrinsic factors such as sleep disturbance also impacting
on chronic pain26,27. Altered sleep quality and reduced
circadian rhythmicity are also common in those with
chronic pain28. Chronic pain can also be commonly
reported in those with neurological diseases29.
Chronic pain phenotyping
The relationship between injury and other peripheral
insult, consequent acute pain and the subsequent devel-
opment of chronic pain has not been fully explained. Not
everyone who undergoes major surgery or is badly injured
will develop chronic pain, for example30, and the degree of
joint damage in osteoarthritis often does not match the
severity of chronic pain experienced31. Conversely, com-
plex regional pain syndrome (CRPS) can in rare cases be
incited by minor peripheral insult such as insertion of a
needle32–34. Structural and functional changes in the
brain and spinal cord are associated with the development
and maintenance of chronic pain, such as aberrant
feedback between the spinal cord and brain30,35,36, and
affective brain regions are involved in chronic pain per-
ception37–41. It is also unlikely that there are legitimate
cut-off points or thresholds for localised and widespread
chronic pain, with chronic pain instead existing on a
continuous spectrum42. Thus, exploration of the mole-
cular mechanisms underlying chronic pain is likely to
beneﬁt from a focus on pain phenotypes relating to
chronic pain as a neuropathological trait in its own right.
Conditional false discovery rate (cFDR) analyses
An alternative strategy for identifying genetic variation
contributing to complex traits is to make use of existing
GWAS summary statistic outputs within more powerful
discovery approaches, such as the cFDR approach43. The
cFDR approach makes better use of the genetic overlap
between traits or conditions to discover loci based on
their pleiotropic effects in each phenotype separately, as
the strength of evidence for involvement of a locus in a
primary trait may be enhanced by consideration of the
strength of evidence for the same locus in an associated
secondary trait. In the case of chronic pain, the associa-
tion with mood disorders and mood-related traits is of
substantial interest, as improved understanding of the
biological underpinnings of this overlap may stimulate the
development of novel treatment strategies.
cFDR analyses have been used to ﬁnd novel variants
associated with schizophrenia, type 2 diabetes, Alzheimer
disease, bipolar disorder and systolic blood pressure43–46.
This therefore represents a promising and potentially more
cost-effective method for identifying new single nucleotide
polymorphisms (SNPs) associated with complex traits by
maximising the utility of existing GWAS outputs.
In the study reported here we aimed to ﬁnd chronic
pain-associated SNPs using cFDR analysis, with MDD as
the secondary trait. In addition, we sought to discover loci
with pleiotropic effects on these two phenotypes. We have
chosen to focus on an aspect of chronic pain related to
pain severity—chronic pain grade (CPG).
The power to detect CPG-associated SNPs was
increased by leveraging the additional information coming
from the correlation between predisposing loci for CPG
and for MDD. Overall, we found six CPG-associated and
nine MDD-associated SNPs. In addition, pleiotropic
effects of four LRFN5 SNPs were observed. These ﬁndings
contribute to our understanding of the biological under-
pinnings of chronic pain and a component of its shared
biology with MDD.
Methods
Phenotype deﬁnition and source data
For chronic pain in the cFDR analysis, summary sta-
tistics from a GWAS carried out collaboratively with
Pﬁzer-23andMe Inc7 were used. Brieﬂy, chronic pain
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severity was assessed via CPG;11, on a scale from 0 (no
chronic pain reported) to 4 (high intensity, high disability,
severely limiting chronic pain). Characteristic pain
intensity, days in pain, time since onset, disability score
and disability days were quantiﬁed and used to calculate a
CPG category per individual11, through a questionnaire
consisting of seven question items.
The GWAS of CPG was then carried out by 23andMe in
collaboration with Pﬁzer, using data from 23 301 unre-
lated individuals of white European descent (10 543
individuals with CPG levels 1–4 combined, 12 758 indi-
viduals with CPG level 0; Supplementary Table 1). For
MDD, summary statistics from a recent case-control
GWAS meta-analysis47 were provided by the Psychiatric
Genomics Consortium (PGC) after removal of data from
23andMe and UK Biobank participants, yielding a dataset
originating from an analysis using 43,028 cases and 87,522
controls. Thus, none of the participants contributing to
the CPG summary statistics overlapped with those con-
tributing to the MDD summary statistics. Phenotype
deﬁnitions, study population demographics and meta-
analysis procedures for the MDD GWAS have been
described previously47.
Data preparation and LD pruning
A dataset of SNPs for which a p-value for association,
chromosome position data and rsID were available in both
MDD and CPG datasets was compiled. This was then LD
pruned as follows. Firstly, PLINK-format genotype data,
for each SNP in the newly compiled CPG-MDD summary-
statistic dataset, was extracted from the UK Biobank
genotype data (approved application 6553). Pruning was
carried out using command line PLINK (version 1.9)—
indep-pairwise function. From each SNP-pair with r2 > 0.2
within a 50-SNP window of the lead SNP, one was
removed according to PLINK’s greedy pruning algorithm,
the window slid along 5 SNPs, and the pruning repeated.
This resulted in an LD-pruned dataset of 774,292 SNPs
with association data available for both MDD and CPG.
cFDR analyses
cFDR is an extension of local-area false-discovery rate
(FDR), which is in turn a re-thinking of Benjamini &
Hochberg’s ‘tail-end’ false discovery rate procedure48–51.
The tail-end FDR procedure is concerned with controlling
the FDR at a pre-deﬁned level and deciding the maximum
test statistic value from a list of ordered test statistic
values that allows for this49. Local FDR reframes the FDR
as a Bayesian posterior probability that the SNP in ques-
tion is not associated with the disease or trait, given its
association test statistic50,51.
cFDR analysis of GWAS summary statistics extends
local FDR, with the result being the posterior probability
that the SNP in question is not associated with the
primary phenotype, given its association test statistic
value for both the primary phenotype and for a secondary,
related phenotype. This allows for exploitation of any
underlying pleiotropic genetic architecture, believed to be
ubiquitous in human complex disease52,53.
cFDR and conjunctional cFDR (ccFDR) values for each
SNP for CPG given MDD and vice versa were calculated
(Formula 1) as previously detailed48 using the statistical
software R (version 3.3.3).
cFDR ¼ Pr H0 ið Þ pi  Pi; pj  Pj


  ¼ pi
Pr pi  Pi pj  Pj


 
ð1Þ
The cFDR value for a SNP obtained from the above
formula is the probability that the SNP is not associated
with the primary phenotype, given its strength of
association with the secondary phenotype. The ccFDR
was obtained via taking the higher of the two cFDR values
obtained for each SNP. The signiﬁcance threshold chosen
was cFDR (and ccFDR) ≤ 0.01.
Genomic context analyses
The genomic context for SNPs with signiﬁcant cFDR
values in either analysis was examined. The R package
‘rsnps’ was used to extract data from records in NCBI
dbSNP (https://www.ncbi.nlm.nih.gov/snp). Gene context
for each SNP was examined in the UCSC Genome
Browser (build GRCh38/hg38)54, using a window of
0.5Mbp around each SNP and data from the GENCODE
v24 track, validated or reviewed by either Refseq or
SwissProt staff. The presence of cis-eQTLs close to the
signiﬁcant SNPs was investigated using the IGV eQTL
Browser55 web interface.
Further exploration of pleiotropy in LRFN5
Regression models were run to examine associations
between genotype at a SNP identiﬁed as pleiotropic in the
ccFDR analysis and relevant phenotypes in data from the
UK Biobank (chronic pain, MDD, age attended assess-
ment centre and sex; approved applications 10302, 6553).
Genotype at rs11846556 (the SNP with the lowest ccFDR)
in UK Biobank individuals was coded as number of effect-
associated alleles (0, 1, 2 copies of the A allele).
UK Biobank participants were asked via a touchscreen
questionnaire about “pain types experienced in the last
month” (ﬁeld ID 6159) during baseline investigations.
Possible answers were: ‘None of the above’; ‘Prefer not to
answer’; pain at seven different body sites (head, face,
neck/shoulder, back, stomach/abdomen, hip, knee); or ‘all
over the body’. The seven body-site pain options were not
mutually exclusive, but if a participant chose ‘pain all over
the body’ they could not then select any other pain sites.
Where patients reported recent pain at one or more body
Johnston et al. Translational Psychiatry           (2019) 9:310 Page 3 of 10
sites, or all over the body, they were additionally asked
(category ID 100048) whether this pain had lasted for
3 months or longer.
A dichotomous chronic pain variable was deﬁned as the
presence of chronic pain in at least 1 site (or all over the
body) for longer than 3 months. Those who did not report
pain of that duration were assigned to a control group.
In addition to this dichotomous ‘presence of chronic
pain’ variable, a chronic pain variable capturing infor-
mation about the number of sites of chronic pain was also
created (chronic pain category; treated as an ordinal
variable in regression models), again employing the
3 month minimum duration criterion: 0= no chronic
pain, 1= single site, 2= 2–3 sites, 3= 4–7 sites, 4= all
over the body (Nicholl et al 2014). Individuals giving
‘prefer not to answer’ and ‘do not know’ answers were
excluded from all analyses.
MDD cases were ascertained according to Davis et al.56
from a subset of UK Biobank participants who completed
a detailed the mental health questionnaire assessment (n
= 157 366). Controls consisted of those with no mood
disorder; those with bipolar disorder were excluded from
analyses. An ordinal MDD phenotype (MDD severity) was
also obtained by classifying MDD by number of episodes:
0= no mood disorder, 1= single episode MDD, 2=
recurrent MDD.
A UK Biobank dataset where all individuals had com-
plete information on age, sex, rs11846556 genotype and
chronic pain variables was assembled (n= 469 253, Sup-
plementary Table 2). Logistic regression of chronic pain
(case-control) on rs1186556 genotype (adjusted for age
and sex) and ordinal regression of chronic pain category
on rs1186556 genotype (adjusted for age and sex) were
then carried out to assess the relationship between SNP
genotype and chronic pain.
A second dataset where all individuals had complete
information on age, sex, rs11846556 genotype and MDD
variables was assembled (n= 122,286, Supplementary
Table 3). Logistic regression of MDD (case-control) on
rs11846556 genotype (adjusted for age and sex), and
ordinal regression of MDD severity on rs11846556 gen-
otype (adjusted for age and sex) were then performed to
assess the relationship between SNP genotype and MDD.
A ﬁnal dataset, where all individuals had complete
information on age, sex, genotype, chronic pain and MDD
variables was assembled (n= 121,246, Supplementary
Table 4). Logistic regressions of MDD (case-control) on
chronic pain (case-control) and genotype (adjusted for age
and sex), and of chronic pain (case-control) on MDD
(case-control) and genotype (adjusted for age and sex)
were then carried out, to assess whether any relationship
between MDD and SNP genotype was attenuated by
chronic pain, and whether any relationship between SNP
genotype and chronic pain was attenuated by MDD.
P values for ordinal regression estimates were obtained
via comparing the t value obtained to that of a normal
t-distribution. Standard errors were used to calculate 95%
CI values for ordinal regression output. All models were
adjusted for age and sex, both of which were highly sig-
niﬁcant in all cases. Some models were additionally
adjusted for the phenotype (pain or MDD) not being
tested as the outcome variable.
Results
cFDR and ccFDR analyses
The cFDR approach was used to identify variants
associated with CPG, MDD, or both together in a pleio-
tropic fashion. Eleven SNPs in total were found at cFDR ≤
0.01 (Table 1), six of which, located on chromosomes 12
and 14, were associated with CPG and nine of which,
located on chromosomes 1 and 14, were associated with
MDD. Four of these 11 SNPs, all located within a 131 kbp
region on chromosome 14, were found to be pleiotropic
(ccFDR ≤ 0.01). A lookup table of the top 50 cFDR results,
ordered by cFDR value with MDD as the primary trait, is
provided in Supplementary Table 5.
Genomic context
The SNPs associated with CPG only were located close
to SLC16A7 on chromosome 12 (Supplementary Table 6a,
6b), while the SNPs associated with MDD only were
located within a gene-dense region on chromosome 1
containing LINC01360, LRRIQ3, FPGT, FPGT-TNNI3K,
amongst other genes (Supplementary Table 6b) or close
to (upstream of) or within LRFN5 on chromosome 14
(Supplementary Table 6a, 6b). The SNPs found to be
pleiotropic were also located within LRFN5 on chromo-
some 14 (Supplementary Table 6a, 6b). The pleiotropic
LRFN5 SNPs were all located just upstream of the 5′-most
promoter, or within a large intron close to the 5′-end of
the gene. The SNPs associated with MDD only were also
located within this intron, or were located a little further
upstream of the gene. The CPG-only SNPs were all
located downstream of SLC16A7. One of the pleiotropic
SNPs on chromosome 14, rs11157241, is located approx.
30 kbp upstream of LRFN5.
GTeX eQTL lookups revealed that some of these
phenotype-associated SNPs were also associated with
expression levels of nearby genes. A SNP associated only
with MDD, on chromosome 1 (rs35641559), was found to
be signiﬁcantly associated with expression of a long non-
coding RNA gene LINC01360 in the testis (FDR < 0.05,
Supplementary Table 6c). The MDD-associated and
pleiotropic SNPs on chromosome 14 are all signiﬁcantly
associated with expression of LRFN5 in a range of tissues,
including brain, heart, adipose tissue and spleen (Sup-
plementary Table 6c). The CPG-associated SNPs on
chromosome 12 were not signiﬁcantly associated with
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expression of any gene in the eQTL database (Supple-
mentary Table 6c).
Single-tissue eQTL lookups of rs11846556 showed dif-
ferent trends in expression pattern of LRFN5 with 0, 1 and
2A alleles, with a trend towards increased expression in
the cerebellum and cerebellar hemisphere associated with
homozygosity for the A allele (Fig. 1a, b respectively), and
decreased expression in tibial artery and transformed
ﬁbroblasts associated with increasing number of copies of
the A allele at this SNP locus (Fig. 1c, d respectively).
Association between rs11846556 genotype and MDD and
chronic pain in UK Biobank
To further examine pleiotropic variants within LRFN5,
regression models were used to assess the strength of
association between rs11846556 genotype and each of the
two phenotypes of interest, chronic pain and MDD. Gen-
otype at this SNP was associated with signiﬁcantly
increased risk for chronic pain (Table 2A; FDR-adjusted
p= 0.0008), with each additional copy of the A allele
increasing the odds of having chronic pain by 2% (OR=
1.02). rs11846556 genotype was also associated with
chronic pain category (Table 2B), with each additional
copy of the A allele associated with an OR of 1.02 per
chronic pain category (FDR-adjusted p= 4.4 × 10−5).
Genotype at rs11846556 was not signiﬁcantly associated
with MDD (Table 2A) or with MDD severity (Table 2B).
rs11846556 genotype accounted for 0.29% of the variance
in chronic pain presence and 0.25% of the variance in
chronic pain category (estimated using McFadden’s R2,
adjusting for age and sex). rs11846556 genotype was no
longer associated with presence of chronic pain after
adjustment for MDD status (FDR-adj p= 0.096), but the
adjustment did yield a larger effect size (0.017 vs 0.015 in
the MDD-adjusted and non-adjusted models, respectively).
Discussion
CPG-associated SNPs
The SNPs associated with CPG only were located close
to SLC16A7, which encodes monocarboxylate transporter
2 (MCT2). In the central nervous system, MCT2 is
involved in high afﬁnity, proton-coupled transport of
metabolites (particularly lactate) into neurons and may
play a role in neuronal uptake of energy substrates
released by glia57,58. MCT2 is localised to the post-
synaptic compartment in many human neurons and may
have a specialised role in synaptic functioning59,60. Reg-
ulation of SLC16A7 has also been linked to disorders of
the brain: loss or under-expression has been associated
with temporal-lobe epilepsy61 and it may be expressed
and methylated at different levels in psychotic patients
versus controls62.
MDD-associated SNPs
The SNP on chromosome 1 associated with MDD only
was located close to LRRIQ3 and FPGT. LRRIQ3 encodes
leucine-rich repeat (LRR) and IQ motif containing protein
3, a calcium-channel component. LRR-domain containing
proteins in general are involved in cell-cell communica-
tion, including processes involved in innate immunity and
neuronal development63,64. FPGT encodes fucose-1-
phosphate guanylyltransferase, a protein involved in the
Table 1 Loci identiﬁed from cFDR analysis.
rsID Position Alleles Beta (CPG) P (CPG) OR (MDD) P (MDD) cFDR (CPG) cFDR (MDD) ccFDR
rs4904790 14:42242623 C/T −0.03 1.44E-03 1.042 1.37E-05 0.02 3.58E-03 0.02
rs1584317 14:42213816 C/G 0.028 4.48E-03 0.96 4.59E-06 0.029 3.57E-03 0.03
rs11846556 14:42183025 A/G −0.037 1.11E-04 1.05 2.98E-07 5.57E-04 3.76E-05 5.57E-04
rs10131184 14:42166111 A/G 0.035 2.82E-04 0.95 2.53E-08 8.46E-04 7.10E-06 8.46E-04
rs8015100 14:42095232 A/T −0.033 6.67E-04 1.06 1.50E-09 6.67E-04 9.27E-07 6.67E-04
rs11157241 14:42051771 C/T 0.035 2.91E-04 0.94 4.44E-09 5.83E-04 1.28E-06 5.83E-04
rs10138559 14:41975989 C/T −0.02 0.03 1.042 1.04E-06 0.1 5.25E-03 0.1
rs10872954 14:41948768 A/G −0.026 6.45E-03 1.04 7.68E-06 0.053 7.02E-03 0.053
rs149981001 12:60264802 C/T 0.2 6.24E-08 1.087 0.0181 1.06E-03 0.018 0.018
rs147573737 12:60231575 C/T −0.2 2.09E-07 0.917 0.023 2.21E-03 0.023 0.023
rs35641559 1:73760104 C/T 0.02 0.03 0.961 2.08E-06 0.1 8.83E-03 0.11
Alleles are given as effect allele/other; effect allele is deﬁned as the allele for which association with the trait was tested in the original (CPG or MDD) GWAS. rsIDs for
SNPs associated with both MDD and CPG (pleiotropic SNPs) (ccFDR < 0.01) are shown in bold
Position position given as chromosome:base pair location, cFDR (CPG) cFDR for CPG conditioning on MDD, Beta (CPG)/p (CPG) effect size and p-value from the CPG
GWAS, cFDR (MDD) cFDR for MDD conditioning on CPG, OR (MDD)/p (MDD) effect size (odds ratio for the effect allele) and p-value from the MDD GWAS
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Table 2 Analysis of associations between rs11846556 genotype and chronic pain/MDD.
Beta SE OR p FDR-adj. p Additional adjuster
(A)
CP (dichot.) 0.015 0.004 1.02 2.63E-04 7.89E-04
CP (dichot.) 0.017 0.008 1.02 0.048 0.096 MDD (dichot)
MDD 0.014 0.009 1.01 ns
MDD 0.011 0.010 1.01 ns CP (dichot)
Beta SE p FDR-adj. p
(B)
CPC 0.018 0.004 7.26E-06 4.36E-05
MDD severity 0.014 0.009 ns
(A) results of logistic regression models with dichotomous chronic pain (CP(dichot.)) and major depressive disorder (MDD) variables as outcomes and SNP genotype as
predictor. SE= standard error of the beta coefﬁcient value, OR= odds ratio. Ns= non-signiﬁcant (p > 0.05)
(B) results of ordinal regression models with chronic pain category and MDD severity variables as outcomes and SNP genotype as predictor. SE= standard error of the
beta coefﬁcient, ns= non-signiﬁcant (p > 0.05)
Fig. 1 Expression of LRFN5 in brain and periphery. Boxplot output from single-tissue eQTL lookups (GTEx IGV eQTL Browser) of rs11846556,
showing rank normalised gene expression values for LRFN5. a Cerebellum, b cerebellar hemisphere, c tibial artery and d transformed ﬁbroblasts.
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alternative (salvage) pathways of fucose metabolism65.
Fucose metabolism is important in a variety of cell-cell
communication and host-microbe interaction situations,
but is also important during neuronal development65.
Variants in the LRRIQ3 region have been previously
associated with schizophrenia66, neurodevelopmental
disorders67 and migraine68.
Pleiotropic SNPs in LRFN5
The signiﬁcantly associated SNPs on chromosome 14
found within or close to LRFN5 were either associated
with MDD only or were pleiotropic and associated with
both CPG and MDD. Due to the LD-based pruning
carried out before the cFDR analysis, the MDD-only and
pleiotropic SNPs are not in strong linkage disequilibrium
and may thus be tagging different functional variants,
potentially acting on risk in different ways. LRFN5
encodes leucine-rich repeat (LRR) and ﬁbronectin type 3
domain-containing protein 5. Proteins in the LRFN
family span the plasma membrane, and their extra-
cellular domains are thought to participate in the cell-
cell interactions necessary for both neuronal develop-
ment69,70 and synapse formation71. Lrfn5, along with
another member of the Lrfn protein family, Lrfn2, may
induce both inhibitory and excitatory presynaptic dif-
ferentiation in nearby neuronal cells72, a process that
may play a critical role in brain development and func-
tion73. As a family, these genes are primarily expressed in
the central nervous system. Polymorphic markers within
or close to LRFN5 have been reported to be associated
with progressive autism and familial schizophrenia74,75.
Reduced expression of Lrfn5 has also been reported to
contribute to neuro-inﬂammation76. Each of the four
pleiotropic SNPs has opposing directions of effect in
MDD and CPG. For example, the effect allele at
rs11846556 is associated with an increase in CPG but
with reduced risk of MDD. This may be explained by
structural and connectivity-related changes in the brain
which facilitate development and by the possibility that
the maintenance of chronic pain might involve neuro-
genesis and synaptic plasticity35,41,77, whereas impaired
neurogenesis is associated with depression78,79. Addi-
tionally, differing expression patterns of LRFN5 in the
brain and CNS versus the periphery may be involved in
the opposing direction of effect associated with pleio-
tropic SNPs. Finally, as the SNPs were non-signiﬁcantly
associated in the original studies (conventional GWAS
analyses of CPG) this means that although effect sizes
differ in direction the conﬁdence intervals for effect
estimates of these SNPs on CPG will include zero, and
may therefore not be truly opposing directions of effect.
cFDR analyses using p values indicate pleiotropy in terms
of signiﬁcant cFDR-derived association, rather than
informing on or calculating new effect sizes.
Cis-eQTLs
SNPs within and close to LRFN5 on chromosome 14,
and in the region close to long non-coding RNA gene
LINC01360 on chromosome 1, were found to be cis-
eQTLs. rs35641559 on chromosome 1, associated with
MDD only, was found to be signiﬁcantly associated with
LOC105378800 expression levels in the testis. All four
pleiotropic SNPs on chromosome 14, were found to be
signiﬁcantly associated with LRFN5 expression levels in a
range of tissues, including the brain. Further investigation
of potential regulatory roles for these or other nearby
variants is warranted.
Role of rs11846556 in the biology of chronic pain and
depression
Pleiotropy broadly refers to genetic variants (such as
SNPs) being associated with effects in more than one
trait52. This pleiotropy can be either biological (also
known as horizontal) or mediated (also known as ver-
tical). Biological pleiotropy refers to genetic variants
being associated with effects in two or more traits via
independent mechanisms or pathways, whereas mediated
pleiotropy describes a genetic variant associated with an
effect in one trait, which then is associated with changes
in a second trait—in other words the changes in the
second trait are only associated with the genetic variant
through the variant’s association with the ﬁrst trait.
Number of A alleles at rs11846556, one of the pleio-
tropic SNPs identiﬁed here, was found to be associated
with risk of chronic pain (and with higher values of the
chronic pain category phenotype), but not with MDD
risk or severity (in the UK Biobank cohort), and the
effect size for the chronic pain association was not
attenuated by inclusion of MDD in the regression
model. This relationship is consistent with mediated
pleiotropy rather than biological pleiotropy, i.e., a
pathway in which genotype inﬂuences chronic pain risk,
which in turn affects MDD risk, rather than inﬂuencing
both by separate mechanisms. Formal mediation ana-
lyses was beyond the scope of this study primarily due to
probable sequential ignorability violation and unmea-
sured confounders80,81.
As discussed above, each of the 4 SNPs tagged as
pleiotropic, including rs11846556, are also cis-eQTLs for
LRFN5. The SNP we explored in more detail, rs11846556,
is a cis-eQTL of LRFN5 in the cerebellum and cerebral
hemisphere, along with tibial artery (GTEx single-tissue
eQTL lookup). The number of A alleles at this SNP is
signiﬁcantly associated with increased expression of
LRFN5 in CNS tissues, but with a trend towards decreased
expression in peripheral tissues (Fig. 1a–d), suggesting the
existence of tissue-speciﬁc regulatory effects. This SNP is
also a cis-eQTL for expression of a long intergenic non-
coding RNA (Gencode ID: ENSG00000258636.1) on the
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reverse strand with respect to LRFN5, but only in spleen
and aorta.
Alterations in synaptic plasticity and neurogenesis in
the hippocampus, which is often non-normal in cases of
neuropathic pain, may underlie some of the cognitive and
affective deﬁcits seen in patients with major depression82.
However, in cases where depression is a downstream
consequence of chronic pain, its onset may be inﬂuenced
by lifestyle and other ‘above-the-skin’ factors that also
operate downstream of chronic pain, rather than as a
more direct result of synaptic changes related to LRFN5
expression levels.
Our data therefore suggest that rs11846556 genotype is
signiﬁcantly associated with chronic pain, but not with
MDD, and that the relationship between chronic pain and
genotype is not attenuated by MDD—pleiotropic effects
of related to rs11846556 on chronic pain and MDD
appear to be mediated rather than biological. Possession
of more copies of the A allele at this locus is associated
with increased LRFN5 expression levels in the CNS, which
may exert its effect on transition to a chronic pain state
after a prior insult through consequent alterations to
brain network connectivity.
Strengths and limitations
A key strength of this study lies in its enhanced power,
using the cFDR approach, to detect the contribution of
genetic variants to chronic pain relative to previous
genome-wide approaches. Limitations include the self-
reported nature of the chronic pain phenotype. In addi-
tion, the questions asked in the two studies were slightly
different, generating chronic pain measures that may be
capturing different aspects of the overall phenotype. ‘CPG’
as assessed in the Pﬁzer-23andMe GWAS may be cap-
turing a more direct severity-related phenotype, whereas
‘chronic pain category’ as assessed in UKB is likely to be
capturing a different aspect of chronic pain susceptibility
related to sensitivity of the response to multiple insults, or
to propensity to report. Despite this subtle distinction, we
were able to demonstrate that an LRFN5 SNP is asso-
ciated with both these phenotypic pain measures.
Conclusions
In this study six novel SNPs were found to be associated
with CPG, a measure of pain severity. cFDR analyses also
increased power to ﬁnd MDD-associated variants in
comparison to genome-wide signiﬁcance thresholds.
ccFDR analyses revealed evidence of pleiotropic effects of
variants in LRFN5. The regions around the signiﬁcant
SNPs contain genes involved in, amongst other processes,
neuronal cell metabolism and development, innate
immunity and cell-cell interaction. These regions have also
been previously implicated in a range of neurodevelop-
mental and psychiatric disorders. One of the pleiotropic
SNPs identiﬁed on chromosome 14 (rs11846556), which is
a cis-eQTL of LRFN5 in cerebellum and cerebral hemi-
sphere, was found to be associated with chronic pain but
not MDD in UK Biobank. This provides intriguing pre-
liminary evidence that the pleiotropy associated with var-
iation in LRFN5 may be mediated rather than horizontal.
Additionally, although the genetic correlation between
depression and chronic pain in terms of CPG7 and
comorbidity have been previously reported, this study
highlights a speciﬁc locus, possible mechanisms, and fur-
ther detail on pleiotropy between the two conditions.
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